Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Slides:



Advertisements
Similar presentations
A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.
Advertisements

Hematology The Study of Blood Blood contains cells, proteins, and sugars Red blood cells transport oxygen- erythrocytes White blood cells are part of the.
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,
Targeted downregulation of platelet CLEC-2 occurs through Syk-independent internalization by Viola Lorenz, David Stegner, Simon Stritt, Timo Vögtle, Friedemann.
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Do HSCs divide asymmetrically?
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Patient A.
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,
by Henrik Frederiksen, and Kai Schmidt
Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura
Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study by Lori-Ann Linkins,
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Tax fingerprint in adult T-cell leukemia
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy by Chun.
How I treat elderly patients with myeloma
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim.
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with.
by Daniel W. Bougie, Ana I. Benito, Luis I
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
by Rong Deng, and Joseph P. Balthasar
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation by Bethan Psaila, James B. Bussel, Matthew.
Reproductive capacity in iron overloaded women with thalassemia major
by Wolfram Springer, Alexander von Ruecker, and Roswitha Dickerhoff
by Jessica A. Reese, Xiaoning Li, Manfred Hauben, Richard H
Small red blood cells mimicking platelets
by Monica Galli, Luisa Ruggeri, and Tiziano Barbui
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development.
by Sabah Sallah, and Jim Y. Wan
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B
Has MRD monitoring superseded other prognostic factors in adult ALL?
Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.
Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea by Françoise Bernaudin, Cécile Arnaud,
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.
Platelet ATP secretion in response to agonist stimulation.
Aggregation tracings of platelets lacking PLCβ2/β3.
Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.
by Wendy Lim, Sara K. Vesely, and James N. George
Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.
Intrapatient variability in cyclosporine blood levels in renal transplant patients. Intrapatient variability in cyclosporine blood levels in renal transplant.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Mean plasma concentrations of ampicillin/sulbactam in plasma of critically ill patients with AKI undergoing extended dialysis (duration depicted by box.
Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis  Karl-Georg Fischer, M.D., Andreas van.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.
How I treat heparin-induced thrombocytopenia and thrombosis
A binding relationship with thrombin
Patient Tregs express normal levels of suppression.
by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio
Cold agglutinin disease
Presentation transcript:

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by Martina Tschudi, Bernhard Lämmle, and Lorenzo Alberio Blood Volume 113(11): March 12, 2009 ©2009 by American Society of Hematology

Anticoagulation intensity at first laboratory monitoring 4 hours after starting lepirudin infusion (investigation cohort). Martina Tschudi et al. Blood 2009;113: ©2009 by American Society of Hematology

Course of platelet count and D-dimer among the 31 patients of the investigation cohort who were within therapeutic ranges already at first monitoring after starting lepirudin. Martina Tschudi et al. Blood 2009;113: ©2009 by American Society of Hematology

Course of platelet count and D-dimer among the 15 patients of the evaluation cohort. Martina Tschudi et al. Blood 2009;113: ©2009 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.